The estimated Net Worth of Michael L Jones is at least $88 Tisíc dollars as of 15 December 2022. Mr. Jones owns over 445 units of Biocryst Pharmaceuticals stock worth over $83,121 and over the last 5 years he sold BCRX stock worth over $4,851. In addition, he makes $0 as Executive Director - Finance a Principal Accounting Officer at Biocryst Pharmaceuticals.
Michael has made over 4 trades of the Biocryst Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 445 units of BCRX stock worth $4,851 on 15 December 2022.
The largest trade he's ever made was exercising 8,600 units of Biocryst Pharmaceuticals stock on 1 December 2022 worth over $12,212. On average, Michael trades about 1,585 units every 64 days since 2020. As of 15 December 2022 he still owns at least 10,753 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Jones stock trades at the bottom of the page.
Michael L. Jones CPA serves as Executive Director - Finance, Principal Accounting Officer of the Company. He joined the Company in 2011 and has served as the Company’s Director, Financial Accounting since 2013. Prior to joining the Company, he held various finance and accounting positions with Talecris Biotherapeutics, Inc., a biopharmaceutical company, and Salix Pharmaceuticals, Inc., a specialty pharmaceutical company. He is a certified public accountant and holds a B.A. in Business Administration from North Carolina State University and a Master of Business Administration from the University of South Carolina.
Michael Jones is 50, he's been the Executive Director - Finance a Principal Accounting Officer of Biocryst Pharmaceuticals since 2020. There are 18 older and 4 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... a Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: